Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma

American Journal of Clinical Pathology

Volumn 138, Issue 6, 2012, Pages 796-802

  Cohen, David A ^a   Dabbs, David J ^a   Cooper, Kristine L ^b   Amin, Milon ^a   Jones, Terrell E ^a   Jones, Mirka W ^a   Chivukula, Mamatha ^a   Trucco, Giuliana A ^a   Bhargava, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Breast carcinoma; Hormone receptors; Interobserver agreement; Semiquantitative H score

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CORRELATION COEFFICIENT; FEMALE; H SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATHOLOGIST; PRIORITY JOURNAL; QUANTITATIVE STUDY; RATING SCALE; SCORING SYSTEM; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS;

EID: 84869213641     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP6DKRND5CKVDD     Document Type: Article

References (32)

1. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
2. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481. (Pubitemid 29220854)
3. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637-5644. (Pubitemid 46631303)
4. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(suppl 6):S1-S21; quiz S22-S23.
5. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol. 2005;12:10-19. (Pubitemid 40614485)
6. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168. (Pubitemid 28144151)
7. McCarty KS, Jr., Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716-721. (Pubitemid 16237466)
8. Bhargava R, Striebel J, Beriwal S, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444-455.
9. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008;21:1255-1261.
10. Kraus JA, Dabbs DJ, Beriwal S, et al. Semi-quantitative immunohistochemical assay versus Oncotype DX((R)) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol. 2012;25:869-876.
11. Bartko JJ. The intraclass correlation coefficient as a measure of reliability. Psychol Rep. 1966;19:3-11.
12. McGraw PE, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Meth. 1996;1:30-46. (Pubitemid 126421252)
13. Schrout PE, Fleiss JL. Intraclass correlation: uses in assessing rater reliability. Psychol Bull. 1979;86:420-428.
14. Conger AJ. Integration and generalisation of kappas for multiple raters. Psychol Bull. 1980;88:322-328.
15. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76:378-382.
16. Landis J, Koch G. The measurment of observer agreement for categorical data. Biometrics. 1977;33:159-174. (Pubitemid 8054849)
17. Tamoxifen for early breast cancer: an overview of the randomised trials: Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
18. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545-1554. (Pubitemid 39627082)
19. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-1581. (Pubitemid 44680908)
20. Osborne CK, McGuire WL. Therapy for cancer of the breast: current status of steroid hormone receptors. West J Med. 1979;130:401-407. (Pubitemid 9216459)
21. Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer. 2010;116:1431-1439.
22. Bhargava R, Dabbs DJ, Beriwal S, et al. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol. 2011;24:367-374.
23. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273-4278.
24. Wells CA, Sloane JP, Coleman D, et al. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union: an interlaboratory study. Virchows Arch. 2004;445:119-128. (Pubitemid 39215542)
25. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723-728. (Pubitemid 34457006)
26. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125-130. (Pubitemid 30075056)
27. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123:16-20. (Pubitemid 40066167)
28. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst. 2008;100:836-844.
29. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23:5148-5154.
30. Terry J, Torlakovic EE, Garratt J, et al. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/ Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2009;17:375-382.
31. Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473-2481.
32. Nassar A, Cohen C, Agersborg SS, et al. A new immunohistochemical ER/PR image analysis system: a multisite performance study. Appl Immunohistochem Mol Morphol. 2011;19:195-202.